Chicago-based biotechnology company Tempus has secured $200 million in Series F funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced May 30 and led by Baillie Gifford.
According to its Crunchbase profile, "Tempus is a technology company that has built an operating system to battle cancer. It is on a mission to redefine how genomic data is used in a clinical setting. Their goal is for each patient to benefit from the treatment of others who came before by enabling physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform."
The four-year-old startup has raised seven previous funding rounds, including a $110 million Series E round in 2018.
Over the past year, 17 Chicago-based artificial intelligence companies have secured venture funding, totaling $367 million in new investment to the local industry.
In other local funding news, mobile apps and information services company BigTime Software announced a $14 million Series B funding round on May 30, led by Wavecrest Growth Partners.
According to Crunchbase, "BigTime Software develops cloud-based time-tracking, billing and project management software for professional services firms and licensed OEM partners. It offers browser-based interface for practice management that allows professional services firms to instantly deploy and connect to existing back-office services. BigTime Software also provides time and expense tracking, WIP management, billing and invoicing, task and workflow management and more."
Founded in 2002, the company has raised two previous rounds, including a $413,168 debt financing round in 2014.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.
